GLPwatch
Xultophy vs Zepbound
Drug comparison
Last updated 2026-05-28 15:46 UTCXultophy is a once-daily injection for type 2 diabetes that contains the active ingredient liraglutide, made by Novo Nordisk. Zepbound, also an injection, uses tirzepatide and is FDA-approved for obesity and obstructive sleep apnea, while Xultophy is not approved for these conditions.
AI summary of the sources below.
| Xultophy | Zepbound | |
|---|---|---|
| Active ingredient | liraglutide | tirzepatide |
| Manufacturer | novo-nordisk | eli-lilly |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | obesity, obstructive sleep apnea |
| Label updated | 2025-10-14 | 2026-04-22 |